Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Is Kythera's Double Chin Drug A Winner?

15:57 EDT 2 Apr 2013 | Seeking Alpha
ByC.R. Jackson:

One biotech company I am excited about is Kythera Biopharmaceuticals Inc. (KYTH). Kythera is developing ATX-101, an investigational injectable drug for the reduction of unwanted submental fat, commonly known as "double chin."

Kythera's potential first-in-class injectable drug candidate is a proprietary formulation of synthetic deoxycholic acid, an endogenous compound that is present in the body to promote the natural breakdown of dietary fat. ATX-101 is designed to be a locally-injected drug that causes proximal, preferential destruction of adipocytes, or fat cells, with minimal effect on surrounding tissue..

"Double chins" are caused by a layer of subcutaneous fat around the neck that sags down and creates a wrinkle, that has the resemblance of a second chin. Double chins are most commonly found on the elderly and the obese.

There are no drugs currently available to treat the fatty deposits that causes some double chins. People may opt


Complete Story »

Original Article: Is Kythera's Double Chin Drug A Winner?

NEXT ARTICLE

More From BioPortfolio on "Is Kythera's Double Chin Drug A Winner?"

Search BioPortfolio: